Baseline 68Ga-SSTR and 18F-FDG PET Imaging of Patients with NENs
| Parameter | Data |
| 68Ga-SSTR uptake | 495 (100.0) |
| SUVmax = liver (level 1) | 3 (0.6) |
| Liver<SUVmax≤15 (level 2) | 161 (32.5) |
| 15<SUVmax≤20 (level 3) | 106 (21.4) |
| SUVmax>20 (level 4) | 225 (45.5) |
| 18F-FDG uptake | 495 (100.0) |
| Positive | 382 (77.2) |
| Negative | 113 (22.8) |
| Primary tumor uptake on 18F-FDG PET | |
| No uptake (level 1) | 376 (76.0) |
| SUVmax≤10 (level 2) | 87 (17.6) |
| 10<SUVmax≤15 (level 3) | 16 (3.2) |
| SUVmax>15 (level 4) | 16 (3.20) |
| Primary tumor uptake on 68Ga-SSTR | |
| No uptake (level 1) | 262 (52.9) |
| SUVmax≤15 (level 2) | 102 (20.6) |
| 15<SUVmax≤20 (level 3) | 37 (7.5) |
| SUVmax>20 (level 4) | 94 (19.0) |
| Liver tumor burden on 18F-FDG PET | |
| 0 lesions (level 1) | 239 (48.3) |
| 1 lesion (level 2) | 49 (9.9) |
| 2 to ≤5 lesions (level 3) | 126 (25.5) |
| >5 lesions (level 4) | 77 (15.6) |
| Not assessed | 4 (0.8) |
| Bone tumor burden on 18F-FDG PET | |
| 0 lesions (level 1) | 409 (82.6) |
| 1 lesion (level 2) | 29 (5.9) |
| 2 to ≤5 lesions (level 3) | 36 (7.3) |
| >5 lesions (level 4) | 19 (3.8) |
| Not assessed | 2 (0.4) |
| Lymph node tumor burden on 18F-FDG PET | |
| 0 lesions (level 1) | 362 (73.1) |
| 1 lesion (level 2) | 55 (11.1) |
| 2 to ≤5 lesions (level 3) | 58 (11.7) |
| >5 lesions (level 4) | 13 (2.6) |
| Not assessed | 7 (1.4) |
| Lung tumor burden on 18F-FDG PET | |
| 0 lesions (level 1) | 463 (93.5) |
| 1 lesion (level 2) | 22 (4.4) |
| 2 to ≤5 lesions (level 3) | 6 (1.2) |
| >5 lesions (level 4) | 4 (0.8) |
| Liver tumor burden on 68Ga-SSTR PET | |
| 0 lesions (level 1) | 76 (15.4) |
| 1 lesion (level 2) | 32 (6.5) |
| 2 to ≤5 lesions (level 3) | 153 (30.9) |
| >5 lesions (level 4) | 234 (47.3) |
| Liver tumor 68Ga-SSTR uptake | |
| No uptake (level 1) | 77 (15.6) |
| SUVmax≤15 (level 2) | 117 (23.6) |
| 15<SUVmax≤20 (level 3) | 90 (18.2) |
| SUVmax>20 (level 4) | 211 (42.6) |
Data are numbers followed by percentages in parentheses.